← Back to Company DatabaseVisit Website
Arcus Biosciences
Next-generation cancer immunotherapies targeting the tumor microenvironment.
PublicHayward, CAFounded 2015
About
Arcus Biosciences develops innovative cancer immunotherapies that target key immune checkpoints and pathways in the tumor microenvironment. The company has a broad pipeline of small molecule and antibody programs aimed at overcoming immune suppression in tumors. Arcus has a significant partnership with Gilead Sciences for its oncology portfolio.
Total Funding
$800MKey Product
Domvanalimab (anti-TIGIT) immunotherapyGeography
North AmericaKey Investors
Gilead SciencesTaiho VenturesForesite Capital
Focus Areas
Treatment (Therapeutics)Drug Discovery
Technology
ImmunotherapyTargeted Therapy
Cancer Types
LungColorectalPancreaticPan-cancer
Last updated: Feb 4, 2026